Bioliberty raises £7.6m to reduce post-acute readmissions with computer vision and AI
This article covers Bioliberty, an Edinburgh- and Boston-based healthtech startup, which has raised £7.6m ($10.2m) in a growth funding round to accelerate US commercialisation of its Lifehub platform and expand computer vision and care-coordination features for post-acute physical and occupational therapy. The funding aims to support roll-out to large US provider networks and home-based monitoring, targeting post-acute therapists, clinicians and payers seeking objective measures of mobility and functional recovery.
Bioliberty, an Edinburgh- and Boston-based healthtech startup, has raised £7.6m ($10.2m) in a growth funding round to accelerate US commercialisation of its Lifehub platform and expand computer vision and care‑coordination features for post‑acute physical and occupational therapy. The financing includes a £6.1m Series A tranche and follows a £1.5m pre‑Series A in 2025, and comes as the company pushes into large US provider networks and home‑based monitoring.
Why it matters
Objective measures of mobility and functional recovery are increasingly important as health systems shift to value‑based payment models. Bioliberty is positioning its technology as a source of the functional data clinicians and payers need to reduce readmissions, protect margins and evidence shared savings in models such as CMS’ Transforming Episode Accountability Model. The company cites research showing patients whose physical function is not accurately assessed before discharge face a threefold higher risk of hospital readmission, underlining why post‑acute providers are looking for better measurement and tracking tools.
Inside the product
Bioliberty’s core product, Lifehub Clinic, combines computer vision, AI and robotics to monitor functional recovery and support more intensive therapy sessions in post‑acute settings. The company is also developing Lifehub Home to extend monitoring and progress tracking after patients leave in‑person therapy.
Since launching Lifehub Clinic in mid‑2025, Bioliberty says its system has been adopted by several large US post‑acute providers, including a multicentre partnership with the country’s third largest rehabilitation provider and work with Sheltering Arms Institute. Research collaborations continue with the Abilities Research Center at Mt. Sinai and the IDEAS Center at the US Department of Veterans Affairs’ Central Virginia VA Health Care System. Bioliberty holds eight patents across its Lifehub and Lifeglov technologies, both FDA registered.
Who are the investors?
The headline financing is structured around a £6.1m Series A, led by a £3m investment from the Scottish National Investment Bank. Existing investors Archangels, Eos Advisory, Old College Capital and Hanna Capital SEZC participated, and new investor Conduit Connect joined the round. The company previously raised £1.5m in a pre‑Series A in mid‑2025; since its 2023 seed round Bioliberty says it has raised about £13m in total from public and private backers.
The Scottish National Investment Bank is Scotland’s development bank and focuses on long‑term investments that deliver commercial returns alongside wider public missions such as innovation and place. Archangels is one of the UK’s largest angel syndicates, active in early‑stage tech and life sciences investments in Scotland.
As part of the financing, two experienced US post‑acute leaders join Bioliberty’s board: Russell Bailey, President of Lifepoint Rehabilitation at Lifepoint Health, and Dana Prommel Strauss, Lead Director, Public Policy and Government Affairs at CVS Health. Their appointments are aimed at strengthening clinical and commercial ties with large US provider systems.
In the announcement, Russell Bailey, PT, FACHE, President of Lifepoint Rehabilitation at Lifepoint Health, said:
Throughout my leadership career, I have evaluated numerous emerging technologies, and over the past year, Bioliberty has significantly stood out. The seamless integration into high-intensity clinical workflows and the generation of actionable data for teams have been remarkable. I've witnessed how the platform enhances clinical outcomes while providing care teams and leaders with the visibility needed to standardize care across an expanding post-acute network. I'm thrilled to support Bioliberty as they continue to scale and deliver exceptional value for providers, ultimately ensuring excellent quality outcomes for patients.
In the announcement, Dana Prommel Strauss, DPT, Lead Director, Public Policy and Government Affairs at CVS Health, said:
The acceleration of value-based care and interoperability solutions have created an urgent demand for objective data that delivers actionable insights and predicts patient pathways to reduce the total cost of care. Bioliberty is enhancing physical and occupational therapists hands-on time with patients while capturing the 'missing link' of functional mobility data needed to improve discharge planning and reduce readmissions. These critical insights are what the post-acute space has been waiting for.
If you're researching potential backers in this space:
- Explore our list of healthtech venture capital firms in the UK
- Browse our directory of healthtech angel investors in the UK
Founder perspective
In the announcement, Rowan Armstrong, co‑founder and chief executive officer at Bioliberty, said:
Our team is pleased with the initial success of Lifehub Clinic in the U.S. market, helping post-acute care providers improve patient outcomes through intelligent therapy delivery and discharge planning that incorporates functional data. We look forward to leveraging the expertise of our expanded Board of Directors to further the impact of this work. With this investment, we are expanding how we measure functional recovery through computer vision and AI-driven assessments to build the predictive capability of our product, and to commercialize a system extending those insights into the home.
Armstrong and the board appointments signal a deliberate push to pair clinical credibility with product development and US market access. The funding is earmarked for continued product R&D, US commercial roll‑out and the launch of Lifehub Home for ongoing remote monitoring.
The bigger picture
Public development banks and syndicates remain important backers of UK‑based healthtech companies that need capital to prove clinical and commercial models in the US market. Bioliberty’s deal combines public investment, angel syndicate support and strategic access to major US providers — a mix that has become a common route for British healthtech startups aiming to scale across the Atlantic.
The outcome will be one to watch for UK and European health systems too: if objective functional measures become standard practice in post‑acute care, they could reshape discharge pathways and provider economics beyond the US, and influence how insurers and national payers incorporate mobility metrics into value‑based reimbursement.
They've invested in Bioliberty
Get to know these healthtech investors
| Investor | Sector | Stage | Activity | Team | Connect |
|---|---|---|---|---|---|
 Scottish National Investment Bank | 6 investments investments | more info | |||
 Archangels | 9 investments investments | more info | |||
 Eos Venture Partners (Eos Advisory) | 21 investments investments | 7 contacts contacts | |||
 Old College Capital | 12 investments investments | more info | |||
 Hanna Capital SEZC | 2 investments investments | more info |
Click here for a full list of 7,526+ startup investors in the UK